



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/925,576	08/09/2001	Carsten Andersen	10004.204-US	2881
25908 7590 02/23/2007 NOVOZYMES NORTH AMERICA, INC. 500 FIFTH AVENUE SUITE 1600 NEW YORK, NY 10110			EXAMINER RAO, MANJUNATH N	
			ART UNIT	PAPER NUMBER
			1652	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		02/23/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

09/925,576

Applicant(s)

ANDERSEN ET AL.

Examiner

Manjunath N. Rao, Ph.D.

Art Unit

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 November 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 25-30, 50 and 57 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 25-30 and 50, 57 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input checked="" type="checkbox"/> Other: <u>See Continuation Sheet</u> . |

Continuation of Attachment(s) 6). Other: Sequence alignments (11 pages) .

Art Unit: 1652

DETAILED ACTION

Claims 25-30, 50, 57 are currently pending and are present for examination.

Applicants' amendments and arguments filed on 11-21-06, have been fully considered and are deemed to be persuasive to overcome the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. Specifically, Examiner has withdrawn the rejection of claims 25-30, 50 and 57 under 35 USC 112, 1st paragraph for recitation of new matter in view of claim amendments.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 25-30, 50, 57 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a variant amylase enzyme of SEQ ID NO:12 wherein the variant comprises an alteration selected from the group of alterations to amino acid at positions 118, 320 or 458 and wherein the alteration specifically comprises replacing the amino acid at said positions with lysine (K), does not reasonably provide enablement for variant amylase enzyme wherein the variant comprises a polypeptide having at least 90%, 95% or 97% homology with SEQ ID NO: 12, as well as an alteration selected from the group of alterations corresponding to amino acid at position 118, 320 or 458 and wherein the alteration specifically comprises replacing the amino acid at said positions with lysine (K). The specification does not

Art Unit: 1652

enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

Factors to be considered in determining whether undue experimentation is required, are summarized in *In re Wands* (858 F.2d 731, 8 USPQ 2d 1400 (Fed. Cir. 1988)) as follows: (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claim(s).

Claims 25-30, 50, 57 are so broad as to encompass any amylase comprising the modifications at the above mentioned three positions and having 90% through 97% identity to SEQ ID NO: 12. The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of amylases broadly encompassed by the claims. Since the amino acid sequence of a protein determines its structural and functional properties, predictability of which changes can be tolerated in a protein's amino acid sequence and obtain the desired activity requires a knowledge of and guidance with regard to which amino acids in the protein's sequence, if any, are tolerant of modification and which are conserved (i.e. expectedly intolerant to modification), and detailed knowledge of the ways in which the proteins' structure relates to its function. However, in this case the disclosure is limited to the variant amino acid sequence of only SEQ ID NO:12 selected from the group of alterations to amino acid at positions 118, 320 or 458 and wherein the alteration specifically comprises replacing the amino acid at said positions with lysine (K). It would require undue experimentation of the skilled artisan to make and use the claimed polypeptides. The specification is limited to teaching

Art Unit: 1652

the use of SEQ ID NO: 12 with the any one of the above three amino acid modifications as a amylase but provides no guidance with regard to the making of variants and mutants that are 90% to 97% identical to SEQ ID NO 12 or with regard to other uses. In view of the great breadth of the claim, amount of experimentation required to make the claimed polypeptides, the lack of guidance, working examples, and unpredictability of the art in predicting function from a polypeptide primary structure (e.g., see Ngo et al. in *The Protein Folding Problem and Tertiary Structure Prediction*, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495), the claimed invention would require undue experimentation. As such, the specification fails to teach one of ordinary skill how to use the full scope of the polypeptides encompassed by this claim.

While enzyme isolation techniques, recombinant and mutagenesis techniques are known, and it is routine in the art to screen for multiple substitutions or multiple modifications as encompassed by the instant claims, the specific amino acid positions within a protein's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining the desired activity/utility are limited in any protein and the result of such modifications is unpredictable. In addition, one skilled in the art would expect any tolerance to modification for a given protein to diminish with each further and additional modification, e.g. multiple substitutions.

The specification does not support the broad scope of the claims which encompass all modifications and fragments of any amylase with 90% through 97% identity to SEQ ID NO: 12, because the specification does not establish: (A) regions of the protein structure which may be modified without affecting amylase activity; (B) the general tolerance of amylases to modification and extent of such tolerance; (C) a rational and predictable scheme for modifying

Art Unit: 1652

any amino acid residue with an expectation of obtaining the desired biological function; and (D) the specification provides insufficient guidance as to which of the essentially infinite possible choices is likely to be successful.

Thus, applicants have not provided sufficient guidance to enable one of ordinary skill in the art to make and use the claimed invention in a manner reasonably correlated with the scope of the claims broadly including amylases with an enormous number of amino acid modifications to SEQ ID NOS: 12. The scope of the claims must bear a reasonable correlation with the scope of enablement (*In re Fisher*, 166 USPQ 19 24 (CCPA 1970)). Without sufficient guidance, determination of polypeptides having the desired biological characteristics is unpredictable and the experimentation left to those skilled in the art is unnecessarily, and improperly, extensive and undue. See *In re Wands* 858 F.2d 731, 8 USPQ2nd 1400 (Fed. Cir, 1988).

In response to the previous Office action, applicant has again traversed the above rejection arguing that the amended claims are directed to variants having a high degree of homology to SEQ ID NO:12 and that the claims are indeed enabled. Applicant alleges that Examiner has not given proper consideration to many facts that lead to the contrary conclusion that claims are enabled. Applicant also alleges that Examiner has not given due consideration to the very high level of skill in the art in relation to the breadth of the claims. Applicant maintains, as of the time of the invention, it was routine in the art to produce variant enzymes which were at least 90% homologous to a reference sequence and that the literature (both scientific and patent) is voluminous in regard to the ability of the artisan to carryout routine processes to produce variant sequences and that these skills encompass well known molecular biological techniques for creating diversity from a

Art Unit: 1652

known sequence, and include, e.g., enzyme isolation techniques and recombinant mutagenesis techniques etc. Examiner respectfully disagrees. As explained in the rejection as well as in the previous rebuttal to applicant's response to the rejection in the previous Office action, the specification fails to provide enough guidance to make and use the enormous number of variants claimed herein. Without such guidance one of ordinary skill in the art, even with all the available molecular biological techniques, and information such as 3-D data etc. would be subjected to undue experimentation in order to make and test each and every one of the variant that is 90% identical to SEQ ID NO:12.

Applicant argues that the test for determining enablement is not whether any experimentation is required, but rather whether undue experimentation is required which is very true. Applicant argues that the experimentation that would be required by the present invention is clearly not undue, but rather involves only routine molecular biological techniques. Examiner respectfully disagrees. Even though the techniques involve routine molecular biological techniques, experimentation required to make polypeptides that are 90% identical to SEQ ID NO:12 is undue. In response to the Examiner's example to show as to how one of ordinary skill in the art would have to test a minimum number of 19^{485} variants even to make a variant having a single amino acid change, applicant argues that it is incorrect and misses the point of a proper enablement analysis. It is the applicant's position that no where do the claims require the artisan to make all possible variants. Applicant argues, rather, the claims recite a scope which an artisan can reasonably expect the claimed substitutions to apply across. Examiner respectfully disagrees. It is not clear to the Examiner as to how the applicant can claim an extremely large genus of variants and expect that one

Art Unit: 1652

skilled in the art would choose only a few variants and argue that claims are therefore enabled. Examiner cannot examine a claim using that standard. Examiner has to give the broadest interpretation of the claim and cannot resort to an interpretation that is convenient to one group of skilled artisans. While it is true that artisans can make as many variants as they would like or as few as they would like, Examiner cannot focus on the only those who would make few variants and conclude that claims are enabled. In this regard, applicant recites from the Federal Circuit Court decision handed down in *Hybritech v. Monoclonal Antibodies, Inc*, 231 USPQ 61 (Fed. Cir. 1986). Examiner is aware of that decision. However, Examiner takes the position that the fact pattern of that case and the instant application are not one and the same.

In response to the Examiner's argument that the art does not typically engage in the screening of 19⁴⁸⁵ variants applicant argues that it again misses the point as the art does typically engage in screening vast numbers of variants using routine molecular biological techniques and the artisan is not required by any element of the claim to actually screen 19⁴⁸⁵ variants. Examiner finds such an argument as contradictory to applicant's own argument made earlier. On the one hand applicant argues that the artisan need not make all the variants that Examiner has argued and on the other hand applicant also argues that the art typically engages in screening such large numbers. For the sake of argument, even if the art engages in such large screening the number of variants contemplated by the applicant is much larger when one includes the substitutions, additions, deletions and combinations of such substitutions, deletions and additions of amino acids encompassed in the variants that are 90% identical to SEQ ID NO:12.

Art Unit: 1652

In conclusion, it appears applicant argues only keeping in mind as to what is convenient from their point of view and failing to understand the issues involved when claims are analyzed giving the broadest interpretation. Therefore, contrary to applicant's belief claims are not enabled. Hence the rejection is maintained.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 25, 27-28, 30 are rejected under 35 U.S.C. 102(b) as being anticipated by Outtrup et al. (US 5,824,531, issued Oct.1998, and US 5856164, issued Jan 1999). This rejection is based upon the public availability of issued patents. Claims 25, 27-28, 30 of the instant application are drawn to a variant of a parent α -amylase, wherein said variant comprises a

Art Unit: 1652

substitution of a K at an amino acid position selected from the group consisting of 118, 320 and 458 wherein said variant has α amylase activity and an amino acid sequence of at least 90% homology to SEQ ID NO:12. Outtrup et al. disclose such a variant wherein said variant comprises a substitution of a K at amino acid positions 320 and 458 wherein said variant has α amylase activity and an amino acid sequence that is 90% identical to SEQ ID NO:12. The reference does not make it clear whether said parent of the variant is *Bacillus sp.* DSMZ no. 12649 α amylase. However, Examiner takes the position that because the variant satisfies all the claim requirements, the parent of said variant is inherently a *Bacillus sp.* DSMZ no. 12649 α amylase. Therefore, Outtrup et al. anticipate claims 25, 27-28 and 30 as written.

Since the Office does not have the facilities for examining and comparing applicants' parent protein with the parent protein of the prior art, the burden is on the applicant to show a novel or unobvious difference between the parent of the claimed product and the parent enzyme of the product of the prior art (i.e., that the parent protein of the prior art does not possess the same material structural and functional characteristics of the parent of the claimed protein). See *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and *In re Fitzgerald et al.*, 205 USPQ 594.

In response to the above rejection, applicant argues that the rejection is improper on its face. Applicant argues that the Examiner has not pointed to any passage of these references which teaches a protein having a substitution of a K at an amino acid position selected from the group consisting of 118, 320 and 458. Applicant maintains Outtrup et al. does not teach variant enzymes. Outtrup et al. teach the isolation and characterization of wild-type enzymes. Examiner respectfully disagrees. Irrespective of the

Art Unit: 1652

fact whether Outtrup et al. Labels their enzymes as wild-type of variants, the enzyme disclose by Outtrup et al. reads on the claimed variant of SEQ ID NO:12. As opposed to the applicant's argument, Outtrup et al. discloses a polypeptide having the amino acid sequence of SEQ ID NO:2, which is 90% identical to SEQ ID NO:12 claimed here in and comprising a substitution of a K for an R at positions 320 and 458. Examiner has provided a copy of the sequence alignment again, for applicant's convenience. From that sequence alignment, it can be readily seen that the polypeptide of Outtrup et al. reads on the variant claimed herein. Therefore the above rejection is maintained.

Claims 25, 27-28, 30 are rejected under 35 U.S.C. 102(e) as being anticipated by the following twelve US Patents 6093562, 6187576, 6197565, 6204232, 6287826, 6297038, 6361989, 6486113, 6528298, 6673589, 6867031, 6887986. This rejection is based upon patents issued to other inventive entities. Claims 25, 27-28, 30 of the instant application are drawn to a variant of a parent α -amylase, wherein said variant comprises a substitution of a K at an amino acid position selected from the group consisting of 118, 320 and 458 wherein said variant has α amylase activity and an amino acid sequence of at least 90% homology to SEQ ID NO:12. The above references disclose such a variant wherein said variant comprises a substitution of a K at amino acid positions 320 and 458 wherein said variant has α amylase activity and an amino acid sequence that is 90% identical to SEQ ID NO:12. The reference does not make it clear whether said parent of the variant is *Bacillus sp.* DSMZ no. 12649 α amylase. However, Examiner takes the position that because the variant satisfies all the claim requirements, the parent of said variant

Art Unit: 1652

is inherently a *Bacillus sp.* DSMZ no. 12649 α amylase. Therefore, above patents anticipate claims 25, 27-28 and 30 as written.

Since the Office does not have the facilities for examining and comparing applicants' parent protein with the parent protein of the prior art, the burden is on the applicant to show a novel or unobvious difference between the parent of the claimed product and the parent enzyme of the product of the prior art (i.e., that the parent protein of the prior art does not possess the same material structural and functional characteristics of the parent of the claimed protein). See *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and *In re Fitzgerald et al.*, 205 USPQ 594.

In response to the above rejection, applicant again argues that the rejection is improper on its face. Applicant maintains that the Examiner has not pointed to any passage in any of these 12 patents which teaches a protein having a substitution of a K at an amino acid position selected from the group consisting of 118, 320 and 458 and that the Examiner simply concludes this without directing applicant to any specific teaching. Examiner respectfully disagrees. Examiner has not simply concluded that the above patents anticipate the claimed amino acid sequence. Examiner has concluded that the above patents anticipate the claimed amino acid sequence based on searching and analyzing the sequence search results. All of the above patents disclose a sequence that is 90% identical to SEQ ID NO:12 and comprises a change at position 320 and 458. The substituted amino acid at both positions is a K for an R. For the applicant's convenience, Examiner has again included all the sequence alignments which clearly show that the instant claimed polypeptides have already been disclosed. Hence the above rejection is maintained.

Art Unit: 1652

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 25, 27-28, 30 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims of U.S. Patents 6093562, 6187576, 6197565, 6204232, 6297038, 6673589. An obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but an examined application claim is not patentably distinct from the reference claim, because the examined claim is either anticipated by, or would have been obvious over the reference claim. See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi* 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985). Although the conflicting claims are not identical, they are not patentably distinct from each other. Claims 25, 27-28, 30 of the instant application and claims in the reference patents are both directed to variants of amylase having an amino acid sequence that is at least 90% identical to SEQ ID NO:12 and comprising an alteration at an amino acid corresponding to positions 320 and 458 (R to K). Among the different positions claimed in the instant application and in the reference patents the above positions are identical to the positions recited/claimed in all the reference patents. The portion

Art Unit: 1652

of the specification (and the claims) in the reference patents that supports the recited amino acid positions on SEQ ID NO:12 herein includes the embodiments (amino acid positions and amino acid percent identity) that would anticipate the positions claimed in claims 25, 27-28, 30 herein. Claims of the instant application listed above cannot be considered patentably distinct over claims of the reference patents when there is specifically recited embodiment that would anticipate mainly claims 25, 27-28, 30 of the instant application. Alternatively, claims 25, 27-28, 30 cannot be considered patentably distinct over claims of the reference patents when there is specifically disclosed embodiment in the reference patents that supports claims of that patent and falls within the scope of claims 25, 27-28, 30 herein because it would have been obvious to one having ordinary skill in the art to modify claims of the reference by selecting a specifically disclosed embodiment that supports those claims i.e., a variant of a parent glucoamylase with SEQ ID NO:12 comprising changes at positions 320 and 458 and an amino acid sequence that is at least 90% identical to SEQ ID NO:12. One of ordinary skill in the art would have been motivated to do this because that embodiment is disclosed as being a preferred embodiment within claims of the reference patent.

In response to the above rejection, applicant again argues that the rejection is improper on its face. Applicant maintains that the Examiner has not pointed to any passage in any of these 12 patents which teaches a protein having a substitution of a K at an amino acid position selected from the group consisting of 118, 320 and 458 and that the Examiner simply concludes this without directing applicant to any specific teaching. Examiner respectfully disagrees. Examiner has not simply concluded that the above patents already claim the amino acid sequence claimed herein. Examiner has concluded that the above

Art Unit: 1652

patents claim the amino acid sequence claimed herein based on searching and analyzing the sequence search results. All of the above patents claim a sequence that is 90% identical to SEQ ID NO:12 and comprises a change at position 320 and 458. The substituted amino acid at both positions is a K for an R. For the applicant's convenience, Examiner has again included all the sequence alignments which clearly show that the instant claimed polypeptides have already been claimed or would have been obvious. Hence the above rejection is maintained.

Conclusion

None of the claims are allowable.


THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Manjunath N. Rao, Ph.D. whose telephone number is 571-272-

Art Unit: 1652

0939. The Examiner can normally be reached on 7.00 a.m. to 3.30 p.m. If attempts to reach the examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy can be reached on 571-272-0928. The fax phone numbers for the organization where this application or proceeding is assigned is 703-872-9306/9307 for regular communications and for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.



Manjunath N. Rao, Ph.D.
Primary Examiner
Art Unit 1652

February 8, 2007

Db 181 RHGKAWDEVDTENGYDILMTADIDMDHPEVVELRWNGVYNTLGLDGRIDAVKH 240
 QY 241 IKYSFTDWINHVSATGKMFVAFAEFKNDLGAIEYLNKTNWHSVDFVPLHYNLYNA 300
 Db 241 IKYSFTDWINHVSATGKMFVAFAEFKNDLGAIEYLNKTNWHSVDFVPLHYNLYNA 300
 QY 301 SKSGGNYDMRQIFNGTVVQRPMPHATVFDVNDHDSQPEEALSFVEEFKPLAYALTRE 360
 Db 301 SKSGGNYDMRNIENGTVVQRPMPHATVFDVNDHDSQPEEALSFVEEFKPLAYALTRE 360
 QY 361 QGYPVSFYDYGIPHTGVPAMKSKIDPILFARQKAYGRONDYLDHNIIGWTREGNTA 420
 Db 361 QGYPVSFYDYGIPHTGVPAMKSKIDPILFARQKAYGRONDYLDHNIIGWTREGNTA 420
 QY 421 HNSGLATIMSDGAGGKMMFVGRNKAGQVWTDITGNRAGTVTINADGWNFSVNGGVS 480
 Db 421 HNSGLATIMSDGAGGKMMFVGRNKAGQVWTDITGNRAGTVTINADGWNFSVNGGVS 480
 QY 481 IWVWK 485
 Db 481 IWVWK 485

RESULT 18
 US-09-441-313-6

; Sequence 6, Application US/09441313
 ; Patent No. 6887986
 ; GENERAL INFORMATION:
 ; APPLICANT: Svendsen, Allan
 ; APPLICANT: Kjulliff, S ren
 ; APPLICANT: Bisgaard-Frantzen, Henrik
 ; APPLICANT: Bisgaard-Frantzen, Henrik
 ; APPLICANT: Ostergaard, Peter Rabbek
 ; APPLICANT: Rasmussen, Michael Dolberg
 ; APPLICANT: Van Der Zee, Pia
 ; TITLE OF INVENTION: Alkaline Amylase
 ; FILE REFERENCE: 5709,000-US
 ; CURRENT APPLICATION NUMBER: US/09/441,313
 ; CURRENT FILING DATE: 1999-11-16
 ; EARLIER APPLICATION NUMBER: 09/193,068
 ; EARLIER FILING DATE: 1998-11-16
 ; NUMBER OF SEQ ID NOS: 31
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 6
 ; LENGTH: 485
 ; TYPE: PRT
 ; ORGANISM: Bacillus sp.
 US-09-441-313-6

Query Match 96.5%; Score 2613; DB 2; Length 485;
 Best Local Similarity 95.5%; Pred. No. 7.5e-217;
 Matches 463; Conservative 13; Mismatches 9; Indels 0; Gaps 0;
 QY 1 HNGTNGTMMQYFEWYLPNDGNHNRSLDASNLKDKGISAVWIPPAWKASQNDVGYCA 60
 Db 1 HNGTNGTMMQYFEWYLPNDGNHNRSLDASNLKDKGISAVWIPPAWKASQNDVGYCA 60
 QY 61 YDLYDLGEFNGKGTIRTKYGTNRQLQAAYVNAKNSNGIOVYGDVVMNHKGADATEMVRV 120
 Db 61 YDLYDLGEFNGKGTIRTKYGTNRQLQAAYVNAKNSNGIOVYGDVVMNHKGADATEMVRV 120
 QY 121 EVNPNRNQEVSGEYTIETAWTKFDPFGNGNTHSNFKRWYHFDGVNDQSRKLNRIYKF 180
 Db 121 EVNPNRNQEVSGEYTIETAWTKFDPFGNGNTHSNFKRWYHFDGVNDQSRKLNRIYKF 180
 QY 181 RGGKGDWEDVTENGNDYLMYADIDMDHPEVVELRWNGVYNTLGLDGRIDAVKH 240
 Db 181 RGGKGDWEDVTENGNDYLMYADIDMDHPEVVELRWNGVYNTLGLDGRIDAVKH 240
 QY 241 IKYSFTDWINHVSATGKMFVAFAEFKNDLGAIEYLNKTNWHSVDFVPLHYNLYNA 300
 Db 241 IKYSFTDWINHVSATGKMFVAFAEFKNDLGAIEYLNKTNWHSVDFVPLHYNLYNA 300
 QY 301 SKSGGNYDMRQIFNGTVVQRPMPHATVFDVNDHDSQPEEALSFVEEFKPLAYALTRE 360

Db 301 SKSGGNYDMRNIENGTVVQRPMPHATVFDVNDHDSQPEEALSFVEEFKPLAYALTRE 360
 QY 361 QGYPVSFYDYGIPHTGVPAMKSKIDPILFARQKAYGRONDYLDHNIIGWTREGNTA 420
 Db 361 QGYPVSFYDYGIPHTGVPAMKSKIDPILFARQKAYGRONDYLDHNIIGWTREGNTA 420
 QY 421 HNSGLATIMSDGAGGKMMFVGRNKAGQVWTDITGNRAGTVTINADGWNFSVNGGVS 480
 Db 421 HNSGLATIMSDGAGGKMMFVGRNKAGQVWTDITGNRAGTVTINADGWNFSVNGGVS 480
 QY 481 IWVWK 485
 Db 481 IWVWK 485

RESULT 19
 US-08-446-803-2
 ; Sequence 2, Application US/08446803
 ; Patent No. 5824531
 ; GENERAL INFORMATION:
 ; APPLICANT: Ottrup, Helle
 ; APPLICANT: Bisgaard-Frantzen, Henrik
 ; APPLICANT: Ostergaard, Peter Rabbek
 ; APPLICANT: Rasmussen, Michael Dolberg
 ; APPLICANT: Van Der Zee, Pia
 ; TITLE OF INVENTION: Alkaline Amylase
 ; NUMBER OF SEQUENCES: 5
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: No. 58245310 No. 5824531disk of No. 5824531th America
 ; STREET: 405 Lexington Avenue
 ; CITY: New York
 ; STATE: New York
 ; COUNTRY: USA
 ; ZIP: 10174
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent In Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/446,803
 ; FILING DATE: 01-June-1995
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Harrington, James J.
 ; REGISTRATION NUMBER: 38,711
 ; REFERENCE/DOCKET NUMBER: 4157.204-US
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212) 867-0123
 ; TELEFAX: (212) 878-9655
 ; INFORMATION FOR SEQ ID NO: 2:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 485 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: peptide
 US-08-446-803-2

Query Match 90.0%; Score 2437; DB 1; Length 485;
 Best Local Similarity 86.8%; Pred. No. 1.1e-201;
 Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
 QY 1 HNGTNGTMMQYFEWYLPNDGNHNRSLDASNLKDKGISAVWIPPAWKASQNDVGYCA 60
 Db 1 HNGTNGTMMQYFEWYLPNDGNHNRSLDASNLKDKGISAVWIPPAWKASQNDVGYCA 60
 QY 61 YDLYDLGEFNGKGTIRTKYGTNRQLQAAYVNAKNSNGIOVYGDVVMNHKGADATEMVRV 120
 Db 61 YDLYDLGEFNGKGTIRTKYGTNRQLQAAYVNAKNSNGIOVYGDVVMNHKGADATEMVRV 120
 QY 121 EVNPNRNQEVSGEYTIETAWTKFDPFGNGNTHSNFKRWYHFDGVNDQSRKLNRIYKF 180

Claimed
 0-1-9

TELECOMMUNICATION INFORMATION:

TELEPHONE: 212 867 0123
 TELEFAX: 212 867 0298
 INFORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 485 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 US-08-600-656-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
 Best Local Similarity 86.8%; Pred. No. 1.1e-201;
 Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

QY 1 HNGTGTMMQYFEWYLPNDGNHNRLSDASNLKDGISAVWIPPAWKASQNDVGGA 60
 DB 1 HNGTGTMMQYFEWYLPNDGNHNRLSDASNLKDGISAVWIPPAWKASQNDVGGA 60

QY 61 YDLGLGEFNGKQRTIRTKYGTNRNOLQAAVNAKNGIOVYGVVNMHKGADATENVRV 120
 DB 61 YDLGLGEFNGKQRTIRTKYGTNRNOLQAAVNAKNGIOVYGVVNMHKGADATENVRV 120

QY 121 EVNPNRNQVSGEYTIETAWTKFDPGGRNTHSNFKRWYHFDGVDNDQSRKLNRIYKF 180
 DB 121 EVNPNRNQVSGEYTIETAWTKFDPGGRNTHSNFKRWYHFDGVDNDQSRKLNRIYKF 180

QY 181 RGDKGMDWEVDTEGNYDYLWADIDMDHPEVNVNLRNNGVWYTNLTGLDGFRIIDAVKH 240
 DB 181 RGDKGMDWEVDTEGNYDYLWADIDMDHPEVNVNLRNNGVWYTNLTGLDGFRIIDAVKH 240

QY 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNHNSVDFVPLHYNLYNA 300
 DB 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNHNSVDFVPLHYNLYNA 300

QY 301 SKSGNVDYMRQIFNGTVVQHPMAVTFVDNHDSPQEALESFVEWFKPLAYALTRE 360
 DB 301 SKSGNVDYMRQIFNGTVVQHPMAVTFVDNHDSPQEALESFVEWFKPLAYALTRE 360

QY 361 QGYPSPVGYDYGIPTHGVPAKSKIDPILAEARQYAYGRNDYLDHNNIIGWTREGNTA 420
 DB 361 QGYPSPVGYDYGIPTHGVPAKSKIDPILAEARQYAYGRNDYLDHNNIIGWTREGNTA 420

QY 421 HPNSGLATIMSDGAGGNKMFVGNKAGQVWTDITGNRAGTVTINADGNFNSVNGGSVS 480
 DB 421 HPNSGLATIMSDGAGGNKMFVGNKAGQVWTDITGNRAGTVTINADGNFNSVNGGSVS 480

QY 481 IWVK 485
 DB 481 IWVK 485

RESULT 22
 US-09-170-670-2
 Sequence 2, Application US/09170670
 Patent No. 6187576
 GENERAL INFORMATION:
 APPLICANT: Svendsen, Allan
 APPLICANT: Borchert, Torben
 APPLICANT: Bisgard-Frantzen Henrik
 TITLE OF INVENTION: Alpha-Amylase Mutants
 FILE REFERENCE: 5276.200-US
 CURRENT APPLICATION NUMBER: US/09/170.670
 CURRENT FILING DATE: 1998-10-13
 EARLIER APPLICATION NUMBER: 1172/97
 EARLIER FILING DATE: 1997-10-13
 EARLIER APPLICATION NUMBER: 60/063,306
 EARLIER FILING DATE: 1997-10-28
 NUMBER OF SEQ ID NOS: 22
 SOFTWARE: FastSeq for Windows Version 3.0
 SEQ ID NO 2
 LENGTH: 485
 TYPE: PRT

ORGANISM: Bacillus sp.
 US-09-170-670-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
 Best Local Similarity 86.8%; Pred. No. 1.1e-201;
 Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

QY 1 HNGTGTMMQYFEWYLPNDGNHNRLSDASNLKDGISAVWIPPAWKASQNDVGGA 60
 DB 1 HNGTGTMMQYFEWYLPNDGNHNRLSDASNLKDGISAVWIPPAWKASQNDVGGA 60

QY 61 YDLGLGEFNGKQRTIRTKYGTNRNOLQAAVNAKNGIOVYGVVNMHKGADATENVRV 120
 DB 61 YDLGLGEFNGKQRTIRTKYGTNRNOLQAAVNAKNGIOVYGVVNMHKGADATENVRV 120

QY 121 EVNPNRNQVSGEYTIETAWTKFDPGGRNTHSNFKRWYHFDGVDNDQSRKLNRIYKF 180
 DB 121 EVNPNRNQVSGEYTIETAWTKFDPGGRNTHSNFKRWYHFDGVDNDQSRKLNRIYKF 180

QY 181 RGDKGMDWEVDTEGNYDYLWADIDMDHPEVNVNLRNNGVWYTNLTGLDGFRIIDAVKH 240
 DB 181 RGDKGMDWEVDTEGNYDYLWADIDMDHPEVNVNLRNNGVWYTNLTGLDGFRIIDAVKH 240

QY 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNHNSVDFVPLHYNLYNA 300
 DB 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNHNSVDFVPLHYNLYNA 300

QY 301 SKSGNVDYMRQIFNGTVVQHPMAVTFVDNHDSPQEALESFVEWFKPLAYALTRE 360
 DB 301 SKSGNVDYMRQIFNGTVVQHPMAVTFVDNHDSPQEALESFVEWFKPLAYALTRE 360

QY 361 QGYPSPVGYDYGIPTHGVPAKSKIDPILAEARQYAYGRNDYLDHNNIIGWTREGNTA 420
 DB 361 QGYPSPVGYDYGIPTHGVPAKSKIDPILAEARQYAYGRNDYLDHNNIIGWTREGNTA 420

QY 421 HPNSGLATIMSDGAGGNKMFVGNKAGQVWTDITGNRAGTVTINADGNFNSVNGGSVS 480
 DB 421 HPNSGLATIMSDGAGGNKMFVGNKAGQVWTDITGNRAGTVTINADGNFNSVNGGSVS 480

QY 481 IWVK 485
 DB 481 IWVK 485

RESULT 23
 US-09-170-670-8
 Sequence 8, Application US/09170670
 Patent No. 6187576
 GENERAL INFORMATION:
 APPLICANT: Svendsen, Allan
 APPLICANT: Borchert, Torben
 APPLICANT: Bisgard-Frantzen Henrik
 TITLE OF INVENTION: Alpha-Amylase Mutants
 FILE REFERENCE: 5276.200-US
 CURRENT APPLICATION NUMBER: US/09/170.670
 CURRENT FILING DATE: 1998-10-13
 EARLIER APPLICATION NUMBER: 1172/97
 EARLIER FILING DATE: 1997-10-13
 EARLIER APPLICATION NUMBER: 60/063,306
 EARLIER FILING DATE: 1997-10-28
 NUMBER OF SEQ ID NOS: 22
 SOFTWARE: FastSeq for Windows Version 3.0
 SEQ ID NO 8
 LENGTH: 485
 TYPE: PRT
 ORGANISM: Bacillus sp.
 US-09-170-670-8

Query Match 90.0%; Score 2437; DB 2; Length 485;
 Best Local Similarity 86.8%; Pred. No. 1.1e-201;
 Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

QY 1 HNGTGTMMQYFEWYLPNDGNHNRLSDASNLKDGISAVWIPPAWKASQNDVGGA 60

Db 1 HNGTNGTMOYFEWHLPNQGNHNRRLSDASNLKRGITAIWIPPAWKTSQNDVGGA 60
Qy 61 YDLIDGFEFNQKGTIRTKYGTNRQLOQAVALNKSNGIQVYGVVNMHKGADATEMVRV 120
Db 61 YDLIDGFEFNQKGTIRTKYGTNRQLOQAVALNKSNGIQVYGVVNMHKGADATEMVRV 120
Qy 121 EVNPNRNRQSVGEYTIETAWTKFDFPGRGNTHSNFKRWYHFDGVWDQSRKLNRIYKF 180
Db 121 EVNPNRNRQSVGEYTIETAWTKFDFPGRGNTHSNFKRWYHFDGVWDQSRKLNRIYKF 180
Qy 181 RGDGKAWDEVDTEGNGYDILMYADIDMDHPEVNVNLRNMGVYVNTLGLDGFRIIDAVKH 240
Db 181 RGDGKAWDEVDTEGNGYDILMYADIDMDHPEVNVNLRNMGVYVNTLGLDGFRIIDAVKH 240
Qy 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNWNHNSVDFVPLHYNLYNA 300
Db 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNWNHNSVDFVPLHYNLYNA 300
Qy 301 SKSGGNYDMROIENGTVVQHPHMAVTFVDNHDSPQEEALESFVEWFKPLAYALITRE 360
Db 301 SKSGGNYDMROIENGTVVQHPHMAVTFVDNHDSPQEEALESFVEWFKPLAYALITRE 360
Qy 361 QGYSVFGYDYGIPHTHGPVPAKSKIDPILKARQYAYGRONDYLDHNNIIGWREGNTA 420
Db 361 QGYSVFGYDYGIPHTHGPVPAKSKIDPILKARQYAYGRONDYLDHNNIIGWREGNTA 420
Qy 421 HNSGLATTMSDAGGNKMFVGRNKAQOVWTDITGNRAGTVTINADGKNESVNGGSYS 480
Db 421 HNSGLATTMSDAGGNKMFVGRNKAQOVWTDITGNRAGTVTINADGKNESVNGGSYS 480
Qy 481 IWVWK 485
Db 481 IWVWK 485

RESULT 24
US-09-193-068-2
; Sequence 2, Application US/09193068
; Patent No. 6197565
; GENERAL INFORMATION:
; APPLICANT: Svendsen, Allan
; APPLICANT: Kjulliff, S ren
; APPLICANT: Bisgaard-Frantzen, Henrik
; APPLICANT: Andersen, Carsten
; TITLE OF INVENTION: -Amylase Variants
; FILE REFERENCE: 5709.000-US
; CURRENT APPLICATION NUMBER: US/09/193,068
; CURRENT FILING DATE: 1998-11-16
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 485
; TYPE: PRT
; ORGANISM: Bacillus sp.
US-09-193-068-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
Qy 1 HNGTNGTMOYFEWHLPNQGNHNRRLSDASNLKRGITAIWIPPAWKTSQNDVGGA 60
Db 1 HNGTNGTMOYFEWHLPNQGNHNRRLSDASNLKRGITAIWIPPAWKTSQNDVGGA 60
Qy 61 YDLIDGFEFNQKGTIRTKYGTNRQLOQAVALNKSNGIQVYGVVNMHKGADATEMVRV 120
Db 61 YDLIDGFEFNQKGTIRTKYGTNRQLOQAVALNKSNGIQVYGVVNMHKGADATEMVRV 120
Qy 121 EVNPNRNRQSVGEYTIETAWTKFDFPGRGNTHSNFKRWYHFDGVWDQSRKLNRIYKF 180
Db 121 EVNPNRNRQSVGEYTIETAWTKFDFPGRGNTHSNFKRWYHFDGVWDQSRKLNRIYKF 180

Qy 181 RGDGKAWDEVDTEGNGYDILMYADIDMDHPEVNVNLRNMGVYVNTLGLDGFRIIDAVKH 240
Db 181 RGDGKAWDEVDTEGNGYDILMYADIDMDHPEVNVNLRNMGVYVNTLGLDGFRIIDAVKH 240
Qy 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNWNHNSVDFVPLHYNLYNA 300
Db 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNWNHNSVDFVPLHYNLYNA 300
Qy 301 SKSGGNYDMROIENGTVVQHPHMAVTFVDNHDSPQEEALESFVEWFKPLAYALITRE 360
Db 301 SKSGGNYDMROIENGTVVQHPHMAVTFVDNHDSPQEEALESFVEWFKPLAYALITRE 360
Qy 361 QGYSVFGYDYGIPHTHGPVPAKSKIDPILKARQYAYGRONDYLDHNNIIGWREGNTA 420
Db 361 QGYSVFGYDYGIPHTHGPVPAKSKIDPILKARQYAYGRONDYLDHNNIIGWREGNTA 420
Qy 421 HNSGLATTMSDAGGNKMFVGRNKAQOVWTDITGNRAGTVTINADGKNESVNGGSYS 480
Db 421 HNSGLATTMSDAGGNKMFVGRNKAQOVWTDITGNRAGTVTINADGKNESVNGGSYS 480
Qy 481 IWVWK 485
Db 481 IWVWK 485

RESULT 25
US-09-193-068-8
; Sequence 8, Application US/09193068
; Patent No. 6197565
; GENERAL INFORMATION:
; APPLICANT: Svendsen, Allan
; APPLICANT: Kjulliff, S ren
; APPLICANT: Bisgaard-Frantzen, Henrik
; APPLICANT: Andersen, Carsten
; TITLE OF INVENTION: -Amylase Variants
; FILE REFERENCE: 5709.000-US
; CURRENT APPLICATION NUMBER: US/09/193,068
; CURRENT FILING DATE: 1998-11-16
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 485
; TYPE: PRT
; ORGANISM: Bacillus sp.
US-09-193-068-8

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
Qy 1 HNGTNGTMOYFEWHLPNQGNHNRRLSDASNLKRGITAIWIPPAWKTSQNDVGGA 60
Db 1 HNGTNGTMOYFEWHLPNQGNHNRRLSDASNLKRGITAIWIPPAWKTSQNDVGGA 60
Qy 61 YDLIDGFEFNQKGTIRTKYGTNRQLOQAVALNKSNGIQVYGVVNMHKGADATEMVRV 120
Db 61 YDLIDGFEFNQKGTIRTKYGTNRQLOQAVALNKSNGIQVYGVVNMHKGADATEMVRV 120
Qy 121 EVNPNRNRQSVGEYTIETAWTKFDFPGRGNTHSNFKRWYHFDGVWDQSRKLNRIYKF 180
Db 121 EVNPNRNRQSVGEYTIETAWTKFDFPGRGNTHSNFKRWYHFDGVWDQSRKLNRIYKF 180
Qy 181 RGDGKAWDEVDTEGNGYDILMYADIDMDHPEVNVNLRNMGVYVNTLGLDGFRIIDAVKH 240
Db 181 RGDGKAWDEVDTEGNGYDILMYADIDMDHPEVNVNLRNMGVYVNTLGLDGFRIIDAVKH 240
Qy 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNWNHNSVDFVPLHYNLYNA 300
Db 241 IKYSFTRDWLNHVRNATGKMFVAEFAWKNDLGAENYLNKTNWNHNSVDFVPLHYNLYNA 300
Qy 301 SKSGGNYDMROIENGTVVQHPHMAVTFVDNHDSPQEEALESFVEWFKPLAYALITRE 360
Db 301 SKSGGNYDMROIENGTVVQHPHMAVTFVDNHDSPQEEALESFVEWFKPLAYALITRE 360

[illegible]

Query Match	90.0%;	Score 2437;	DB 2;	Length 485;
Best Local Similarity	86.8%;	Prod. No. 1.1e-261;	"	"
Matches 421;	Conservative 36;	Mismatches 28;	Indels 0;	Gaps 0;
1	HHNGTGTMMQYFEWYLPNDGNHNRLLSDASNLKDGISAVWTPPAWKASQNDVCYGA	60		
1	HHNGTGTMMQYFEWHLPNNDGNHNRLLRDDASNLNRGITAIVTPPAWKTSQNDVGYG	60		
61	YDLYDLGEFNQGTIRTKYGTGRNOLQAANVNLKSGIQVYGDVVMNHKGADATEMVRV	120		
61	YDLYDLGEFNQGTVRTKYGTFSQLESIAHLKNNGVQVYGDVVMNHKGADATENVLAV	120		
121	EVPNPNRNOEVSSEYTTIEAWTKFFPQGRGNTHSNFKRWYHFQVDWDQSKLNNRIYKF	180		
121	EVPNPNRNOEISSDYTTIEAWTKFFPQGRGNTYSDFKRWYHFQVDWDQSRQFNRIYKF	180		
181	RGDGGKWDEWDTNGNYDYLYMADIAMDHPVNVNELRNGVMYNTNLGLDGFRIIDAVKH	240		
181	RGDGRANDWEVDSENGNYDYLYMADVMDHPEVNVNELRRNGEWTYNLNLGDFRIIDAVKH	240		
241	IKYSTROWIHNRVSATGQNMFAVAEFWKNDLGAENLYNKTNNHNSVDFVPLHYNLNA	300		
241	IKYSTROWLTHVRNATGEMFAVAEFWKNDLGALENLYNKTNNHNSVDFVPLHYNLNA	300		
301	SKSGGNYDMRQIFNGCTVVQRHPMAVTVFDNHDSQPEEALSFVSEWFKPLAYALTITRE	360		
301	SNSGGNYDMAKLNGTVVQKHHPMAVTVFDNHDSQGESLESFVSEWFKPLAYALTITRE	360		
361	QGYPSVFYGDYIGIPTHGVPAWKSKIDPILEARQKYAYGRNDYLDHNNIIGWTRGNVA	420		

Db 361 QGYPSVFGDYGIPTHSVPAMKAKIDPILARQNFAYGTQHDYFDHNIIGTREGNTT 420
QY 421 HNSGLATIMSDGAGNKWFGVRNKGAGQVWTDITGNRAGTITINADGKGNPSVNGGSVS 480
Db 421 HNSGLATIMSDGPGGKWKMYGQNKAGQVWHDITGNRPGTITINADGKGNPSVNGGSVS 480
QY 481 IWNK 485
Db 481 IWNK 485

RESULT 28
US-09-264-097-5

Sequence 5, Application US/09264097
Patent No. 6287826

GENERAL INFORMATION

APPLICANT: No. 6287826man, Barrie Edmund

APPLICANT: Hendriksen, Hanne Vang

TITLE OF INVENTION: Enzymatic Preparation of Glucose Syrup

FILE OF INVENTION: From Starch

CURRENT APPLICATION NUMBER: US/09/264,097

CURRENT FILING DATE: 1999-03-08

EARLIER APPLICATION NUMBER: PA 0321/98

EARLIER FILING DATE: 1998-03-09

EARLIER APPLICATION NUMBER: 60/079,209

EARLIER FILING DATE: 1998-03-24

NUMBER OF SEQ ID NOS: 8

SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 5

LENGTH: 485

TYPE: PRT

ORGANISM: Bacillus

US-09-264-097-5

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

QY 1 HNGTGTMTQYFEWYLPNDGNHNRRLSDASNLKDGISAVWIPPAWKASQNDVGYGA 60
Db 1 HNGTGTMTQYFEWYLPNDGNHNRRLSDASNLKDGISAVWIPPAWKASQNDVGYGA 60
QY 61 YDYLDELGEFNQGTIRTKYGTNRLOQAAVNAKNSGLOVYGDVVMNHKGADATENVRV 120
Db 61 YDYLDELGEFNQGTIRTKYGTNRLOQAAVNAKNSGLOVYGDVVMNHKGADATENVRV 120
QY 121 EVNPNRNRQESGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVDQSRKLNRIYKF 180
Db 121 EVNPNRNRQESGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVDQSRKLNRIYKF 180
QY 181 RGDGKAWDEVDTENGYDYLMTADYDMDHPEVNNELRWGEWYTNLNLGFRIDAVKH 240
Db 181 RGDGKAWDEVDTENGYDYLMTADYDMDHPEVNNELRWGEWYTNLNLGFRIDAVKH 240
QY 241 IKYSFTDWINHVRSATGNKMFVGRNKGAGQVWTDITGNRAGTITINADGKGNPSVNGGSVS 300
Db 241 IKYSFTDWINHVRSATGNKMFVGRNKGAGQVWTDITGNRAGTITINADGKGNPSVNGGSVS 300
QY 301 SKSGGNYDMRQIPNGTVOGRHPMAVTFVDNHDQSPPEALESFVEWEKPLAYALTLTRE 360
Db 301 SKSGGNYDMRQIPNGTVOGRHPMAVTFVDNHDQSPPEALESFVEWEKPLAYALTLTRE 360
QY 361 QGYPSVFGDYGIPTHSVPAMKAKIDPILARQNFAYGTQHDYFDHNIIGTREGNTA 420
Db 361 QGYPSVFGDYGIPTHSVPAMKAKIDPILARQNFAYGTQHDYFDHNIIGTREGNTT 420
QY 421 HNSGLATIMSDGAGNKWFGVRNKGAGQVWTDITGNRAGTITINADGKGNPSVNGGSVS 480
Db 421 HNSGLATIMSDGPGGKWKMYGQNKAGQVWHDITGNRPGTITINADGKGNPSVNGGSVS 480
QY 481 IWNK 485

Db 481 IWNK 485
RESULT 29
US-09-354-191A-2
Sequence 2, Application US/09354191A
Patent No. 62970380
GENERAL INFORMATION
APPLICANT: Bisgard-Frantzen, Henrik
APPLICANT: Svendsen, Allan
APPLICANT: Borchert, Torben Vedel
TITLE OF INVENTION: AMYLASE VARIANTS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 62970380 No. 62970380disk of No. 62970380th America, Inc.
STREET: 405 Lexington Avenue, Suite 6400
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10174-6401
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25 (BPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/354,191A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/600,656
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Lambiris, Elias J.
REGISTRATION NUMBER: 33,728
REFERENCE/DOCKET NUMBER: 4318.204-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212 867 0123
TELEFAX: 212 867 0298
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 485 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
US-09-354-191A-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

QY 1 HNGTGTMTQYFEWYLPNDGNHNRRLSDASNLKDGISAVWIPPAWKASQNDVGYGA 60
Db 1 HNGTGTMTQYFEWYLPNDGNHNRRLSDASNLKDGISAVWIPPAWKASQNDVGYGA 60
QY 61 YDYLDELGEFNQGTIRTKYGTNRLOQAAVNAKNSGLOVYGDVVMNHKGADATENVRV 120
Db 61 YDYLDELGEFNQGTIRTKYGTNRLOQAAVNAKNSGLOVYGDVVMNHKGADATENVRV 120
QY 121 EVNPNRNRQESGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVDQSRKLNRIYKF 180
Db 121 EVNPNRNRQESGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVDQSRKLNRIYKF 180
QY 181 RGDGKAWDEVDTENGYDYLMTADYDMDHPEVNNELRWGEWYTNLNLGFRIDAVKH 240
Db 181 RGDGKAWDEVDTENGYDYLMTADYDMDHPEVNNELRWGEWYTNLNLGFRIDAVKH 240
QY 241 IKYSFTDWINHVRSATGNKMFVGRNKGAGQVWTDITGNRAGTITINADGKGNPSVNGGSVS 300
Db 241 IKYSFTDWINHVRSATGNKMFVGRNKGAGQVWTDITGNRAGTITINADGKGNPSVNGGSVS 300

QY 301 SKSGNYDMRQIFNGTIVVQRHPMAHVTVDNHDSDQEBALBSFVEWFKPLAYALTRE 360
Db 301 SNSGNYDMKXLLNGTIVVQKHPMAHVTVDNHDSDQESLSFVQEWFKPLAYALTRE 360
QY 361 QGYSVFYGDYIGIPTHGVPAKMSKIDPILARQKAYAGQNDYLDHNNIIGWTREGNTA 420
Db 361 QGYSVFYGDYIGIPTHGVPAKMSKIDPILARQKAYAGQNDYLDHNNIIGWTREGNT 420
QY 421 HPNSGLATIMSDGAGGNKWMFVGRNKAQGVWTDITGNRAGTITINADGWNFSVNGGSVS 480
Db 421 HPNSGLATIMSDGAGGNKWMFVGRNKAQGVWTDITGNRAGTITINADGWNFSVNGGSVS 480
QY 481 IWVWK 485
Db 481 IWVWK 485

RESULT 30
US-09-290-734-2

Sequence 2, Application US/09290734
Patent No. 6361989
GENERAL INFORMATION:
APPLICANT: Svendsen, Allan
APPLICANT: Borchert, Torben Vedel
APPLICANT: Bisgard-Frantzen Henrik
APPLICANT: Outtrup, Helle
APPLICANT: Nielsen, Bjarne Ronfeldt
APPLICANT: Nielsen, Vibeke Skovgaard
APPLICANT: Hoeck, Lisbeth Hedegaard
TITLE OF INVENTION: No. 6361989el -Amylase And -Amylase Mutants
FILE REFERENCE: 5276.400-US
CURRENT APPLICATION NUMBER: US/09/290,734
CURRENT FILING DATE: 1999-04-13
NUMBER OF SEQ ID NOS: 35
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 2
LENGTH: 485
TYPE: PRT
ORGANISM: Bacillus sp.
US-09-290-734-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
QY 1 HNGTGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
Db 1 HNGTGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
QY 61 YLDYDLGEFNOKGTIRTKYGTNRLOQAANALKSNGIOVYGDVVMHKGADATENVRAV 120
Db 61 YLDYDLGEFNOKGTIRTKYGTNRLOQAANALKSNGIOVYGDVVMHKGADATENVRAV 120
QY 121 EVNPNRNEQVSGEYITIAWTKEFDFGRGNTHSNFKRWVHPDGVWDQSRKLNRIYKF 180
Db 121 EVNPNRNEQVSGEYITIAWTKEFDFGRGNTHSNFKRWVHPDGVWDQSRKLNRIYKF 180
QY 181 RGDGKAWDEVDSENGNYDLYADMDHPPEVNNELRWGWTNTNLDGFRIDAVKH 240
Db 181 RGDGKAWDEVDSENGNYDLYADMDHPPEVNNELRWGWTNTNLDGFRIDAVKH 240
QY 241 IKYSFTRDMLTHVRNATGKMFVAEFAEKNDLGAENYLNKTNWNSHVSFVPLHLYNLA 300
Db 241 IKYSFTRDMLTHVRNATGKMFVAEFAEKNDLGAENYLNKTNWNSHVSFVPLHLYNLA 300
QY 301 SKSGNYDMRQIFNGTIVVQRHPMAHVTVDNHDSDQEBALBSFVEWFKPLAYALTRE 360
Db 301 SNSGNYDMKXLLNGTIVVQKHPMAHVTVDNHDSDQESLSFVQEWFKPLAYALTRE 360
QY 361 QGYSVFYGDYIGIPTHGVPAKMSKIDPILARQKAYAGQNDYLDHNNIIGWTREGNTA 420
Db 361 QGYSVFYGDYIGIPTHGVPAKMSKIDPILARQKAYAGQNDYLDHNNIIGWTREGNT 420

QY 421 HPNSGLATIMSDGAGGNKWMFVGRNKAQGVWTDITGNRAGTITINADGWNFSVNGGSVS 480
Db 421 HPNSGLATIMSDGAGGNKWMFVGRNKAQGVWTDITGNRAGTITINADGWNFSVNGGSVS 480
QY 481 IWVWK 485
Db 481 IWVWK 485

RESULT 31

US-09-290-734-8
Sequence 8, Application US/09290734

Patent No. 6361989
GENERAL INFORMATION:
APPLICANT: Svendsen, Allan
APPLICANT: Borchert, Torben Vedel
APPLICANT: Bisgard-Frantzen Henrik
APPLICANT: Outtrup, Helle
APPLICANT: Nielsen, Bjarne Ronfeldt
APPLICANT: Nielsen, Vibeke Skovgaard
APPLICANT: Hoeck, Lisbeth Hedegaard
TITLE OF INVENTION: No. 6361989el -Amylase And -Amylase Mutants
FILE REFERENCE: 5276.400-US
CURRENT APPLICATION NUMBER: US/09/290,734
CURRENT FILING DATE: 1999-04-13
NUMBER OF SEQ ID NOS: 35
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 8
LENGTH: 485
TYPE: PRT
ORGANISM: Bacillus sp.
US-09-290-734-8

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
QY 1 HNGTGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
Db 1 HNGTGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
QY 61 YLDYDLGEFNOKGTIRTKYGTNRLOQAANALKSNGIOVYGDVVMHKGADATENVRAV 120
Db 61 YLDYDLGEFNOKGTIRTKYGTNRLOQAANALKSNGIOVYGDVVMHKGADATENVRAV 120
QY 121 EVNPNRNEQVSGEYITIAWTKEFDFGRGNTHSNFKRWVHPDGVWDQSRKLNRIYKF 180
Db 121 EVNPNRNEQVSGEYITIAWTKEFDFGRGNTHSNFKRWVHPDGVWDQSRKLNRIYKF 180
QY 181 RGDGKAWDEVDSENGNYDLYADMDHPPEVNNELRWGWTNTNLDGFRIDAVKH 240
Db 181 RGDGKAWDEVDSENGNYDLYADMDHPPEVNNELRWGWTNTNLDGFRIDAVKH 240
QY 241 IKYSFTRDMLTHVRNATGKMFVAEFAEKNDLGAENYLNKTNWNSHVSFVPLHLYNLA 300
Db 241 IKYSFTRDMLTHVRNATGKMFVAEFAEKNDLGAENYLNKTNWNSHVSFVPLHLYNLA 300
QY 301 SKSGNYDMRQIFNGTIVVQRHPMAHVTVDNHDSDQEBALBSFVEWFKPLAYALTRE 360
Db 301 SNSGNYDMKXLLNGTIVVQKHPMAHVTVDNHDSDQESLSFVQEWFKPLAYALTRE 360
QY 361 QGYSVFYGDYIGIPTHGVPAKMSKIDPILARQKAYAGQNDYLDHNNIIGWTREGNTA 420
Db 361 QGYSVFYGDYIGIPTHGVPAKMSKIDPILARQKAYAGQNDYLDHNNIIGWTREGNT 420
QY 421 HPNSGLATIMSDGAGGNKWMFVGRNKAQGVWTDITGNRAGTITINADGWNFSVNGGSVS 480
Db 421 HPNSGLATIMSDGAGGNKWMFVGRNKAQGVWTDITGNRAGTITINADGWNFSVNGGSVS 480
QY 481 IWVWK 485
Db 481 IWVWK 485

RESULT 32
US-09-381-687-3
; Sequence 3, Application US/09381687
; Patent No. 6486113
; GENERAL INFORMATION:
; APPLICANT: HATADA, Yoji
; APPLICANT: IKAWA, Kaori
; APPLICANT: ITO, Susumu
; APPLICANT: IGARASHI, Kazuaki
; APPLICANT: HAGIHARA, Hiroshi
; APPLICANT: HAYASHI, Yasuhiko
; APPLICANT: ARAKI, Hiroyuki
; APPLICANT: OZAKI, Katsuya
; TITLE OF INVENTION: MUTANT ALPHA-AMYLASES
; FILE REFERENCE: 2173-0115P
; CURRENT APPLICATION NUMBER: US/09/381.687
; CURRENT FILING DATE: 1999-09-23
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 485
; TYPE: PRT
; ORGANISM: Bacillus sp.
US-09-381-687-3

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
QY 1 HNGTGTMMQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
Db 1 HNGTGTMMQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
QY 61 YLDYDLGEFNQKGTITKTYGTRNLOQAANVAKSNGIOVYGDVVMHKGADATEMVRV 120
Db 61 YLDYDLGEFNQKGTITKTYGTRNLOQAANVAKSNGIOVYGDVVMHKGADATEMVRV 120
QY 121 EVNPNRNRQEVSGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVMDQSRKLNRIYKF 180
Db 121 EVNPNRNRQEVSGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVMDQSRKLNRIYKF 180
QY 181 RGDGKDWEDVTEGNGYDLYMADIDMDHPEVNELRNMGVYNTLGLDGRIDAVKH 240
Db 181 RGDGKDWEDVTEGNGYDLYMADIDMDHPEVNELRNMGVYNTLGLDGRIDAVKH 240
QY 241 IKYSFTDRMHNVRNATGKMFVAFWKNDLGAIENYLNKTNWHSVDFVPLHYNLXNA 300
Db 241 IKYSFTDRMHNVRNATGKMFVAFWKNDLGAIENYLNKTNWHSVDFVPLHYNLXNA 300
QY 301 SKSGGNYDMRQIFNGTVVQHPMHAVTFVDNHDQPERALESFVEWFKPLAYALTRE 360
Db 301 SKSGGNYDMRQIFNGTVVQHPMHAVTFVDNHDQPERALESFVEWFKPLAYALTRE 360
QY 361 QGYPVFGDYGYGIPHTGVPAMKSIDPILFARQKAYAGRONDYLDHNNIIGWTREGNTA 420
Db 361 QGYPVFGDYGYGIPHTGVPAMKSIDPILFARQKAYAGRONDYLDHNNIIGWTREGNTA 420
QY 421 HNSGLATIMSDGAGNKMVFGRNKAQOVWTDITGNRAGTVTINADGNGFVNGSGVS 480
Db 421 HNSGLATIMSDGAGNKMVFGRNKAQOVWTDITGNRAGTVTINADGNGFVNGSGVS 480
QY 481 IWVWK 485
Db 481 IWVWK 485

RESULT 33
US-09-545-586-2
; Sequence 2, Application US/09545586
; Patent No. 6528298
; GENERAL INFORMATION:
; APPLICANT: Svendsen, Allan

APPLICANT: Borchert, Torben Vedel
APPLICANT: Bisgard-Frantzen Henrik
APPLICANT: Outtrup, Helle
APPLICANT: Nielsen, Bjarne Ronfeldt
APPLICANT: Nielsen, Vibeke Skovgaard
APPLICANT: Hoeck, Lisbeth Hedegaard
TITLE OF INVENTION: No. 6528298el -Amylase And -Amylase Mutants
FILE REFERENCE: 5276.400-US
CURRENT APPLICATION NUMBER: US/09/545.586
PRIOR FILING DATE: 2000-04-07
PRIOR APPLICATION NUMBER: US/09/290.734
NUMBER OF SEQ ID NOS: 35
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 2
LENGTH: 485
TYPE: PRT
ORGANISM: Bacillus sp.
US-09-545-586-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
QY 1 HNGTGTMMQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
Db 1 HNGTGTMMQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
QY 61 YLDYDLGEFNQKGTITKTYGTRNLOQAANVAKSNGIOVYGDVVMHKGADATEMVRV 120
Db 61 YLDYDLGEFNQKGTITKTYGTRNLOQAANVAKSNGIOVYGDVVMHKGADATEMVRV 120
QY 121 EVNPNRNRQEVSGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVMDQSRKLNRIYKF 180
Db 121 EVNPNRNRQEVSGEYTIETAWTKDFPGRGNTHSNFKRWYHFDGVMDQSRKLNRIYKF 180
QY 181 RGDGKDWEDVTEGNGYDLYMADIDMDHPEVNELRNMGVYNTLGLDGRIDAVKH 240
Db 181 RGDGKDWEDVTEGNGYDLYMADIDMDHPEVNELRNMGVYNTLGLDGRIDAVKH 240
QY 241 IKYSFTDRMHNVRNATGKMFVAFWKNDLGAIENYLNKTNWHSVDFVPLHYNLXNA 300
Db 241 IKYSFTDRMHNVRNATGKMFVAFWKNDLGAIENYLNKTNWHSVDFVPLHYNLXNA 300
QY 301 SKSGGNYDMRQIFNGTVVQHPMHAVTFVDNHDQPERALESFVEWFKPLAYALTRE 360
Db 301 SKSGGNYDMRQIFNGTVVQHPMHAVTFVDNHDQPERALESFVEWFKPLAYALTRE 360
QY 361 QGYPVFGDYGYGIPHTGVPAMKSIDPILFARQKAYAGRONDYLDHNNIIGWTREGNTA 420
Db 361 QGYPVFGDYGYGIPHTGVPAMKSIDPILFARQKAYAGRONDYLDHNNIIGWTREGNTA 420
QY 421 HNSGLATIMSDGAGNKMVFGRNKAQOVWTDITGNRAGTVTINADGNGFVNGSGVS 480
Db 421 HNSGLATIMSDGAGNKMVFGRNKAQOVWTDITGNRAGTVTINADGNGFVNGSGVS 480
QY 481 IWVWK 485
Db 481 IWVWK 485

RESULT 34
US-09-545-586-8
; Sequence 8, Application US/09545586
; Patent No. 6528298
; GENERAL INFORMATION:
; APPLICANT: Svendsen, Allan
; APPLICANT: Borchert, Torben Vedel
; APPLICANT: Bisgard-Frantzen Henrik
; APPLICANT: Outtrup, Helle
; APPLICANT: Nielsen, Bjarne Ronfeldt
; APPLICANT: Nielsen, Vibeke Skovgaard
; APPLICANT: Hoeck, Lisbeth Hedegaard

; TITLE OF INVENTION: No. 6528298el -Amylase And -Amylase Mutants
 ; FILE REFERENCE: 5276.400-US
 ; CURRENT APPLICATION NUMBER: US/09/545,586
 ; CURRENT FILING DATE: 2000-04-07
 ; PRIOR APPLICATION NUMBER: US/09/290,734
 ; PRIOR FILING DATE: 1999-04-13
 ; NUMBER OF SEQ ID NOS: 35
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 8
 ; LENGTH: 485
 ; TYPE: PRT
 ; ORGANISM: Bacillus sp.
 ; US-09-545-586-8

Query Match 90.0%; Score 2437; DB 2; Length 485;
 Best Local Similarity 86.8%; Pred. No. 1.1e-201;
 Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
 QY 1 HHNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
 DB 1 HHNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
 QY 61 YDLYLGEFNGKGTIRTKYGTNRQLQAQVAVNALKNSGIVQYGVVVMNHKGGADATENVAV 120
 DB 61 YDLYLGEFNGKGTIRTKYGTNRQLQAQVAVNALKNSGIVQYGVVVMNHKGGADATENVAV 120
 QY 121 EVNPNRNRQEVSGEYTTIEMTKFDPGGRGNTHSNFKRWYHFDGVDQSKLNRIYKF 180
 DB 121 EVNPNRNRQEVSGEYTTIEMTKFDPGGRGNTHSNFKRWYHFDGVDQSKLNRIYKF 180
 QY 181 RGDGKMDWEVDTEGNGYDYLMTADIMDHPVNVNLRNMGVWYTTNLGLDGFPRIDAVKH 240
 DB 181 RGDGKMDWEVDTEGNGYDYLMTADIMDHPVNVNLRNMGVWYTTNLGLDGFPRIDAVKH 240
 QY 241 IKYSFTRDWLNHVRSATGKNMFAVAFWKNLDGAIENLYLNKTNHNSVDFVPLHYNLYNA 300
 DB 241 IKYSFTRDWLNHVRSATGKNMFAVAFWKNLDGAIENLYLNKTNHNSVDFVPLHYNLYNA 300
 QY 301 SKSGGNDVMDRQIFNGTVVQHPMHAVTFVDNHDSPPEALESFVEEWFKPLAYALITRE 360
 DB 301 SKSGGNDVMDRQIFNGTVVQHPMHAVTFVDNHDSPPEALESFVEEWFKPLAYALITRE 360
 QY 361 QGYPSVFYGDYIGPIPTHGVPAMKSKIDPILFARQKAYGRQNDYLDHNNIIGWTRENTA 420
 DB 361 QGYPSVFYGDYIGPIPTHGVPAMKSKIDPILFARQKAYGRQNDYLDHNNIIGWTRENTA 420
 QY 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGVTITNADGWNFVNGSGVS 480
 DB 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGVTITNADGWNFVNGSGVS 480
 QY 481 IWVKN 485
 DB 481 IWVKN 485

RESULT 35
 US-09-769-864-2
 ; Sequence 2, Application US/09/769864
 ; Patent No. 6673589
 ; GENERAL INFORMATION:
 ; APPLICANT: Borchert, Torben V.
 ; APPLICANT: Svendsen, Allan
 ; APPLICANT: Andersen, Carsten
 ; APPLICANT: Nielsen, Bjarne
 ; APPLICANT: Nissen, Torben L.
 ; APPLICANT: Kjaerulff, Soren
 ; TITLE OF INVENTION: Alpha-Amylase Mutants
 ; FILE REFERENCE: 5368.200-US
 ; CURRENT APPLICATION NUMBER: US/09/769,864
 ; CURRENT FILING DATE: 2001-01-25
 ; PRIOR APPLICATION NUMBER: 09/183,412
 ; PRIOR FILING DATE: 1998-10-30
 ; NUMBER OF SEQ ID NOS: 58

; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 2
 ; LENGTH: 485
 ; TYPE: PRT
 ; ORGANISM: Bacillus sp.
 ; US-09-769-864-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
 Best Local Similarity 86.8%; Pred. No. 1.1e-201;
 Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;
 QY 1 HHNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
 DB 1 HHNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKGSQNDVGYGA 60
 QY 61 YDLYLGEFNGKGTIRTKYGTNRQLQAQVAVNALKNSGIVQYGVVVMNHKGGADATENVAV 120
 DB 61 YDLYLGEFNGKGTIRTKYGTNRQLQAQVAVNALKNSGIVQYGVVVMNHKGGADATENVAV 120
 QY 121 EVNPNRNRQEVSGEYTTIEMTKFDPGGRGNTHSNFKRWYHFDGVDQSKLNRIYKF 180
 DB 121 EVNPNRNRQEVSGEYTTIEMTKFDPGGRGNTHSNFKRWYHFDGVDQSKLNRIYKF 180
 QY 181 RGDGKMDWEVDTEGNGYDYLMTADIMDHPVNVNLRNMGVWYTTNLGLDGFPRIDAVKH 240
 DB 181 RGDGKMDWEVDTEGNGYDYLMTADIMDHPVNVNLRNMGVWYTTNLGLDGFPRIDAVKH 240
 QY 241 IKYSFTRDWLNHVRSATGKNMFAVAFWKNLDGAIENLYLNKTNHNSVDFVPLHYNLYNA 300
 DB 241 IKYSFTRDWLNHVRSATGKNMFAVAFWKNLDGAIENLYLNKTNHNSVDFVPLHYNLYNA 300
 QY 301 SKSGGNDVMDRQIFNGTVVQHPMHAVTFVDNHDSPPEALESFVEEWFKPLAYALITRE 360
 DB 301 SKSGGNDVMDRQIFNGTVVQHPMHAVTFVDNHDSPPEALESFVEEWFKPLAYALITRE 360
 QY 361 QGYPSVFYGDYIGPIPTHGVPAMKSKIDPILFARQKAYGRQNDYLDHNNIIGWTRENTA 420
 DB 361 QGYPSVFYGDYIGPIPTHGVPAMKSKIDPILFARQKAYGRQNDYLDHNNIIGWTRENTA 420
 QY 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGVTITNADGWNFVNGSGVS 480
 DB 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGVTITNADGWNFVNGSGVS 480
 QY 481 IWVKN 485
 DB 481 IWVKN 485

RESULT 36
 US-09-769-864-8
 ; Sequence 8, Application US/09769864
 ; Patent No. 6673589
 ; GENERAL INFORMATION:
 ; APPLICANT: Borchert, Torben V.
 ; APPLICANT: Svendsen, Allan
 ; APPLICANT: Andersen, Carsten
 ; APPLICANT: Nielsen, Bjarne
 ; APPLICANT: Nissen, Torben L.
 ; APPLICANT: Kjaerulff, Soren
 ; TITLE OF INVENTION: Alpha-Amylase Mutants
 ; FILE REFERENCE: 5368.200-US
 ; CURRENT APPLICATION NUMBER: US/09/769,864
 ; CURRENT FILING DATE: 2001-01-25
 ; PRIOR APPLICATION NUMBER: 09/183,412
 ; PRIOR FILING DATE: 1998-10-30
 ; NUMBER OF SEQ ID NOS: 58
 ; SOFTWARE: FastSeq for Windows Version 3.0
 ; SEQ ID NO 8
 ; LENGTH: 485
 ; TYPE: PRT
 ; ORGANISM: Bacillus sp.
 ; US-09-769-864-8

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

QY 1 HNGTGTWQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60
DB 1 HNGTGTWQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60
QY 61 YDYLGEFNQKGTIRTKYGRNQLQAAVNALSKNGIQVYGDVVMNHKGGADATENVRAV 120
DB 61 YDYLGEFNQKGTIRTKYGRNQLQAAVNALSKNGIQVYGDVVMNHKGGADATENVRAV 120
QY 121 EVNPNRNOEVSGETTIEATWTKFPPGCGNTHSNFKRWYHFDGVDWDQSRQFNRIYKF 180
DB 121 EVNPNRNOEVSGETTIEATWTKFPPGCGNTHSNFKRWYHFDGVDWDQSRQFNRIYKF 180
QY 181 RGDGKAWDEVDENGNVDYLMYADIDMDHPEVNNELRNWGVYNTLGLDGRIDAVKH 240
DB 181 RGDGKAWDEVDENGNVDYLMYADIDMDHPEVNNELRNWGVYNTLGLDGRIDAVKH 240
QY 241 IKYSFTRDLWTHVRNATGKEMFAVAEFWKNLGLAENLYNKTNNHNSVDFVPLHYNLYNA 300
DB 241 IKYSFTRDLWTHVRNATGKEMFAVAEFWKNLGLAENLYNKTNNHNSVDFVPLHYNLYNA 300
QY 301 SKSGGNYDMRQIFNGTVVQHPHMAVTFVNDHDSQPEEALSFVEEWFKPLAYALTITRE 360
DB 301 SKSGGNYDMRQIFNGTVVQHPHMAVTFVNDHDSQPEEALSFVEEWFKPLAYALTITRE 360
QY 361 QGYPVSFYGYGIPHTHVPAMKSKIDPILAEARQKAYAGRONDYLDHNNIIGWTRGNTA 420
DB 361 QGYPVSFYGYGIPHTHVPAMKSKIDPILAEARQKAYAGRONDYLDHNNIIGWTRGNTA 420
QY 421 HPNSGLATIMSDGAGGKMWYVGNKAGQVWTDITGNRAGTIVTINADGWGNSVNGSGVS 480
DB 421 HPNSGLATIMSDGAGGKMWYVGNKAGQVWTDITGNRAGTIVTINADGWGNSVNGSGVS 480
QY 481 IWVWK 485
DB 481 IWVWK 485

RESULT 37
US-10-025-648-2
Sequence 2, Application US/10025648
Patent No. 6867031
GENERAL INFORMATION:
APPLICANT: Bisgaard-Frantzen, Henrik
Svendsen, Allan
Borchert, Torben Vedel
TITLE OF INVENTION: AMYLASE VARIANTS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 6867031 No. 6867031disk of No. 6867031th America, Inc.
STREET: 405 Lexington Avenue, Suite 6400
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10174-6401
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/025,648
FILING DATE: 19-Dec-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/600,656
FILING DATE: 13-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: Lambiris, Elias J.
REGISTRATION NUMBER: 33,728

REFERENCE/DOCKET NUMBER: 4318.204-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212 867 0123
TELEFAX: 212 867 0298
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 485 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-025-648-2

Query Match 90.0%; Score 2437; DB 2; Length 485;
Best Local Similarity 86.8%; Pred. No. 1.1e-201;
Matches 421; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

QY 1 HNGTGTWQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60
DB 1 HNGTGTWQYFEWYLPNDGNHNRSLRSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60
QY 61 YDYLGEFNQKGTIRTKYGRNQLQAAVNALSKNGIQVYGDVVMNHKGGADATENVRAV 120
DB 61 YDYLGEFNQKGTIRTKYGRNQLQAAVNALSKNGIQVYGDVVMNHKGGADATENVRAV 120
QY 121 EVNPNRNOEVSGETTIEATWTKFPPGCGNTHSNFKRWYHFDGVDWDQSRQFNRIYKF 180
DB 121 EVNPNRNOEVSGETTIEATWTKFPPGCGNTHSNFKRWYHFDGVDWDQSRQFNRIYKF 180
QY 181 RGDGKAWDEVDENGNVDYLMYADIDMDHPEVNNELRNWGVYNTLGLDGRIDAVKH 240
DB 181 RGDGKAWDEVDENGNVDYLMYADIDMDHPEVNNELRNWGVYNTLGLDGRIDAVKH 240
QY 241 IKYSFTRDLWTHVRNATGKEMFAVAEFWKNLGLAENLYNKTNNHNSVDFVPLHYNLYNA 300
DB 241 IKYSFTRDLWTHVRNATGKEMFAVAEFWKNLGLAENLYNKTNNHNSVDFVPLHYNLYNA 300
QY 301 SKSGGNYDMRQIFNGTVVQHPHMAVTFVNDHDSQPEEALSFVEEWFKPLAYALTITRE 360
DB 301 SKSGGNYDMRQIFNGTVVQHPHMAVTFVNDHDSQPEEALSFVEEWFKPLAYALTITRE 360
QY 361 QGYPVSFYGYGIPHTHVPAMKSKIDPILAEARQKAYAGRONDYLDHNNIIGWTRGNTA 420
DB 361 QGYPVSFYGYGIPHTHVPAMKSKIDPILAEARQKAYAGRONDYLDHNNIIGWTRGNTA 420
QY 421 HPNSGLATIMSDGAGGKMWYVGNKAGQVWTDITGNRAGTIVTINADGWGNSVNGSGVS 480
DB 421 HPNSGLATIMSDGAGGKMWYVGNKAGQVWTDITGNRAGTIVTINADGWGNSVNGSGVS 480
QY 481 IWVWK 485
DB 481 IWVWK 485

RESULT 38
US-09-441-313-2
Sequence 2, Application US/09441313
Patent No. 6887986
GENERAL INFORMATION:
APPLICANT: Svendsen, Allan
APPLICANT: Kyrulff, S ren
APPLICANT: Bisgaard-Frantzen, Henrik
APPLICANT: Andersen, Carsten
TITLE OF INVENTION: -Amylase Variants
FILE REFERENCE: 5709.000-US
CURRENT APPLICATION NUMBER: US/09/441,313
CURRENT FILING DATE: 1999-11-16
EARLIER APPLICATION NUMBER: 09/193,068
EARLIER FILING DATE: 1998-11-16
NUMBER OF SEQ ID NOS: 31
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 2

LENGTH: 485

TYPE: PRT

ORGANISM: Bacillus sp.

US-09-441-313-2

Query Match

Best Local Similarity 90.0%; Score 2437; DB 2; Length 485;

Mismatches 36; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

```

QY 1 HNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60
Db 1 HNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60

QY 61 YLDYDLGEFNGKGTITRTKYGTRNQLQAAVNAKNSNGIQVYGVVNMHKGADATEMVRVAV 120
Db 61 YLDYDLGEFNGKGTITRTKYGTRNQLQAAVNAKNSNGIQVYGVVNMHKGADATEMVRVAV 120

QY 121 EYVNNRNOEVSGETYIEAWTKFDPFGNGTHSNFKRWYHFDGVDWDQSRKLNRIYKF 180
Db 121 EYVNNRNOEVSGETYIEAWTKFDPFGNGTHSNFKRWYHFDGVDWDQSRKLNRIYKF 180

QY 181 RDGKGWDEVDTEGNYDYLMAADIMDHPEVNVNLRNWGVYVNTLGLDGFRIIDAVKH 240
Db 181 RDGKGWDEVDTEGNYDYLMAADIMDHPEVNVNLRNWGVYVNTLGLDGFRIIDAVKH 240

QY 241 IKYSFTRDMLTHVRNATGEMFAVAFWKNDLGALENTLNKTNMNSVDFVPLHYNLYNA 300
Db 241 IKYSFTRDMLTHVRNATGEMFAVAFWKNDLGALENTLNKTNMNSVDFVPLHYNLYNA 300

QY 301 SKSGNYDMROIENGTIVVORHPMAVTFVDNHDQPEALESFVBEWFKPLAYALTIRE 360
Db 301 SKSGNYDMROIENGTIVVORHPMAVTFVDNHDQPEALESFVBEWFKPLAYALTIRE 360

QY 361 QGYPVFYDYGIGIPTHGVPAMKSKIDPILFARQKAYGRONDYLDHNNIIGWTREGNTA 420
Db 361 QGYPVFYDYGIGIPTHGVPAMKSKIDPILFARQKAYGRONDYLDHNNIIGWTREGNTA 420

QY 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGTVTTINADGWNFSVNGGSVS 480
Db 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGTVTTINADGWNFSVNGGSVS 480

QY 481 IWVKN 485
Db 481 IWVKN 485

```

RESULT 39

US-09-441-313-8

Sequence 8, Application US/09441313

Patent No. 6887986

GENERAL INFORMATION:

APPLICANT: Svendsen, Allan

APPLICANT: Kjrulff, S ren

APPLICANT: Bisgaard-Frantzen, Henrik

APPLICANT: Andersen, Carsten

TITLE OF INVENTION: -Amylase Variants

CURRENT APPLICATION NUMBER: US/09/441.313

CURRENT FILING DATE: 1999-11-16

EARLIER APPLICATION NUMBER: 09/193.068

EARLIER FILING DATE: 1998-11-16

NUMBER OF SEQ ID NOS: 31

SOFTWARE: FastSeq for Windows Version 3.0

SEQ ID NO 8

LENGTH: 485

TYPE: PRT

ORGANISM: Bacillus sp.

US-09-441-313-8

Query Match

Best Local Similarity 90.0%; Score 2437; DB 2; Length 485;

Mismatches 36; Conservative 36; Mismatches 28; Indels 0; Gaps 0;

```

QY 1 HNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60
Db 1 HNGTNGTMMQYFEWYLPNDGNHNRRLSDASNLKDKGISAVWIPPAWKASQNDVGYGA 60

QY 61 YLDYDLGEFNGKGTITRTKYGTRNQLQAAVNAKNSNGIQVYGVVNMHKGADATEMVRVAV 120
Db 61 YLDYDLGEFNGKGTITRTKYGTRNQLQAAVNAKNSNGIQVYGVVNMHKGADATEMVRVAV 120

QY 121 EYVNNRNOEVSGETYIEAWTKFDPFGNGTHSNFKRWYHFDGVDWDQSRKLNRIYKF 180
Db 121 EYVNNRNOEVSGETYIEAWTKFDPFGNGTHSNFKRWYHFDGVDWDQSRKLNRIYKF 180

QY 181 RDGKGWDEVDTEGNYDYLMAADIMDHPEVNVNLRNWGVYVNTLGLDGFRIIDAVKH 240
Db 181 RDGKGWDEVDTEGNYDYLMAADIMDHPEVNVNLRNWGVYVNTLGLDGFRIIDAVKH 240

QY 241 IKYSFTRDMLTHVRNATGEMFAVAFWKNDLGALENTLNKTNMNSVDFVPLHYNLYNA 300
Db 241 IKYSFTRDMLTHVRNATGEMFAVAFWKNDLGALENTLNKTNMNSVDFVPLHYNLYNA 300

QY 301 SKSGNYDMROIENGTIVVORHPMAVTFVDNHDQPEALESFVBEWFKPLAYALTIRE 360
Db 301 SKSGNYDMROIENGTIVVORHPMAVTFVDNHDQPEALESFVBEWFKPLAYALTIRE 360

QY 361 QGYPVFYDYGIGIPTHGVPAMKSKIDPILFARQKAYGRONDYLDHNNIIGWTREGNTA 420
Db 361 QGYPVFYDYGIGIPTHGVPAMKSKIDPILFARQKAYGRONDYLDHNNIIGWTREGNTA 420

QY 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGTVTTINADGWNFSVNGGSVS 480
Db 421 HPNSGLATIMSDGAGGNKMFVGRNKGQVWTDITGNRAGTVTTINADGWNFSVNGGSVS 480

QY 481 IWVKN 485
Db 481 IWVKN 485

```

RESULT 40

US-08-446-803-1

Sequence 1, Application US/08446803

Patent No. 5824531

GENERAL INFORMATION:

APPLICANT: Otttrup, Helle

APPLICANT: Bisgaard-Frantzen, Henrik

APPLICANT: Ostergaard, Peter Rahbek

APPLICANT: Rasmussen, Michael Dolberg

APPLICANT: Van Der Zee, Pia

TITLE OF INVENTION: Alkaline Bacillus Amylase

NUMBER OF SEQUENCES: 5

CORRESPONDENCE ADDRESS:

ADDRESSEE: No. 58245310 No. 5824531disk of No. 5824531th America

STREET: 405 Lexington Avenue

CITY: New York

STATE: New York

COUNTRY: USA

ZIP: 10174

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/446,803

FILING DATE: 01-June-1995

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Harrington, James J.

REGISTRATION NUMBER: 38,711

REFERENCE/DOCKET NUMBER: 4157.204-US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 867-0123

TELEFAX: (212) 878-9655

INFORMATION FOR SEQ ID NO: 1: